Compare United States Oil ETF (USO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Oil ETF vs Viatris Inc — how do they compare? United States Oil ETF trades at $148.34 (market cap $1.90B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 10.5× United States Oil ETF's market cap, and Viatris Inc pays a 2.75% dividend while United States Oil ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold United States Oil ETF for 21 Days and Viatris Inc for 57 Days on average.
| USO | VTRS | |
|---|---|---|
Market Cap | $1.90B | $20.03B |
Volume | 5,932,922 | 14,109,977 |
52-Week High | $161.86 | $18.27 |
52-Week Low | $66.17 | $9.74 |
Typical Hold Time | 21 Days | 57 Days |
Sector | — | Health |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USO is trading at $148.32, up 3.06% today with a bullish technical signal supported by moving averages. The stock shows neutral oscillator readings with RSI at 63.03 suggesting balanced momentum. Recent news highlights oil market volatility from Middle East tensions and OPEC+ production decisions, creating both supply risks and price pressures.
The outlook remains cautiously optimistic given geopolitical tensions supporting oil prices, though G7 reserve releases and potential supply disruptions create conflicting forces. Key resistance sits at $150 with support at $146, making current levels critical for near-term direction amid volatile energy market conditions.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
